SCHEMBL3969628

SCHEMBL3969628

CC(C)CC(NS(=O)(=O)Cc1ccccc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 1/20 0.55
HTT P42858 1/20 0.55
KMT2A Q03164 1/20 0.55
SLC1A3 P43003 1/20 0.55
SLC1A2 P43004 1/20 0.55
SLC1A1 P43005 1/20 0.55
MME P08473 2/20 0.51
ITGB3 P05106 1/20 0.50
ITGA2B P08514 1/20 0.50
MMP1 P03956 2/20 0.49
MMP2 P08253 2/20 0.49
MMP9 P14780 2/20 0.49
MMP13 P45452 2/20 0.49
CYP2C19 P33261 1/20 0.49
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
LTA4H P09960 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15251810 1.00 ALDH1A1 (0.55) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL15251696 1.00 ALDH1A1 (0.55) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL7434669 0.90 ALDH1A1 (0.54) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL17792880 0.90 ALDH1A1 (0.54) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL17789292 0.86 ALDH1A1 (0.50) ALDH1A1MEN1HTTKMT2ASLC1A3
SCHEMBL6738450 0.85 MME (0.48) ALDH1A1MEN1KMT2AMMEITGB3
SCHEMBL6738452 0.85 MME (0.48) ALDH1A1MEN1KMT2AMMEITGB3
SCHEMBL23265260 0.85 MMP13 (0.44) ALDH1A1MEN1KMT2AMMEITGB3
SCHEMBL18775042 0.85 CTSK (0.52) ALDH1A1MEN1HTTKMT2ACA2
SCHEMBL28367643 0.85 CTSK (0.52) ALDH1A1MEN1HTTKMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP claimed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO claimed
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20240091184-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2024-03-21 US disclosed
CN-116370448-A Modulators of SESTRIN-GATOR2 interactions and uses thereof 纳维托制药有限公司 2023-07-04 CN disclosed
US-11679090-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2023-06-20 US disclosed
CN-110809467-B Modulators of SESTRIN-GATOR2 interactions and uses thereof 纳维托制药有限公司 2023-03-10 CN disclosed
EP-3364958-B1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARM INC (US) 2023-01-04 EP disclosed
EP-4112611-A2 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2023-01-04 EP disclosed
US-11325924-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-10 US disclosed
EP-1747212-A2 PROCESS FOR MAKING N-SULFONATED-AMINO ACID DERIVATIVES Merck and Co., Inc. (US) 2007-01-31 EP disclosed
WO-2005118529-A2 PROCESS FOR MAKING N-SULFONATED-AMINO ACID DERIVATIVES MERCK & CO., INC. (US) 2005-12-15 WO disclosed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240091184-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF GATD3, GABRR2, GABRR3 ALDH1A1 3585/4885MEN1 2509/4885HTT 1544/4885
US-11679090-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 ALDH1A1 3585/4885MEN1 2509/4885HTT 1544/4885
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 ALDH1A1 3585/4885MEN1 2509/4885HTT 1544/4885
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 ALDH1A1 3364/4885MEN1 1180/4885HTT 1221/4885
US-11325924-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 ALDH1A1 3585/4885MEN1 2509/4885HTT 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.